Rational Advisors Inc. Boosts Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Rational Advisors Inc. increased its holdings in Eli Lilly and Company by 558.2% during Q2, owning 2,784 shares worth approximately $2.17 million at the quarter's end.
• Despite recent price target adjustments by analysts, including reductions by JPMorgan Chase and Daiwa Capital Markets, the consensus rating for Eli Lilly remains a "Moderate Buy" with an average target price of $938.61.
• Eli Lilly reported strong Q2 earnings, posting $6.31 EPS, significantly exceeding expectations and achieving a year-over-year revenue growth of 37.6% to $15.56 billion.

Rational Advisors Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 558.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,784 shares of the company's stock after buying an additional 2,361 shares during the quarter. Rational Advisors Inc.'s holdings in Eli Lilly and Company were worth $2,170,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Hobbs Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC lifted its position in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after buying an additional 12 shares in the last quarter. O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the period. Ascent Capital Management LLC increased its position in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Willner & Heller LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the 1st quarter. Willner & Heller LLC now owns 854 shares of the company's stock valued at $705,000 after acquiring an additional 13 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.6%

Eli Lilly and Company stock opened at $825.86 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The firm's 50-day moving average is $768.01 and its 200-day moving average is $768.14. The company has a market cap of $781.65 billion, a P/E ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday, September 16th. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Berenberg Bank reissued a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, HSBC upped their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $938.61.

Insider Activity

In other news, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.